Michael Jaff
Directeur/Membre du Conseil chez HEARTBEAM, INC.
Fortune : 82 444 $ au 30/04/2024
Profil
Michael R.
Jaff is the founder of Embolitech LLC, a company founded in 2016, where he holds the title of Chief Strategic Officer.
He is currently the Director at Access Vascular, Inc. and an Independent Director at HeartBeam, Inc., both of which are his current positions.
In the past, he worked as the Medical Director- Fireman Vascular Center at The General Hospital Corp.
In terms of education, Dr. Jaff completed his undergraduate degree at Dickinson College, obtained a doctorate from Kirksville College of Osteopathic Medicine, Inc., and also attended Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
HEARTBEAM, INC.
0,16% | 24/07/2023 | 41 935 ( 0,16% ) | 82 444 $ | 30/04/2024 |
Postes actifs de Michael Jaff
| Sociétés | Poste | Début |
|---|---|---|
| HEARTBEAM, INC. | Directeur/Membre du Conseil | 24/07/2023 |
Embolitech LLC
 Embolitech LLC Miscellaneous Commercial ServicesCommercial Services Embolitech LLC provides thrombomatrix technology. The firm’s initial research areas focus on the removal of organized thrombi and emboli. It’s Thrombomatrix technology will redefine treatment of peripheral vascular emboli and thrombi. The company was founded by Gary Ansel and Michael R. Jaff in 2016 and is headquartered in Austin, TX. | Fondateur | 01/01/2016 |
Access Vascular, Inc.
 Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Michael Jaff
| Sociétés | Poste | Fin |
|---|---|---|
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Formation de Michael Jaff
| Dickinson College | Undergraduate Degree |
| Kirksville College of Osteopathic Medicine, Inc. | Doctorate Degree |
| Harvard Business School | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HEARTBEAM, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
The General Hospital Corp.
The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Health Services |
Access Vascular, Inc.
Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Health Technology |
Embolitech LLC
Embolitech LLC Miscellaneous Commercial ServicesCommercial Services Embolitech LLC provides thrombomatrix technology. The firm’s initial research areas focus on the removal of organized thrombi and emboli. It’s Thrombomatrix technology will redefine treatment of peripheral vascular emboli and thrombi. The company was founded by Gary Ansel and Michael R. Jaff in 2016 and is headquartered in Austin, TX. | Commercial Services |
